Finding your next opportunity shouldn’t require piecing together multiple databases, alerts and research tools.
Fundz combines its own funding and M&A intelligence with hiring, leadership and other business signals into one connected view of each company, ranks opportunities against your ideal customer profile, and delivers the evidence and verified contacts to act on. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
Matchpoint Therapeutics closes $150M Series B led by Nextech Invest and Norwest to advance oral small molecule pipeline for autoimmune diseases.
Matchpoint Therapeutics announced the successful closing of a $150 million Series B financing round co-led by Nextech Invest and Norwest. New investors including Invus, BB Biotech, T1D Fund, and BOLD Longevity Growth participated alongside existing backers Access Biotechnology, Atlas Venture, and Sanofi Ventures. The proceeds will support clinical development of MPT-062, a first-in-class oral T cell modulator expected to begin trials in 2027, and advancement of the broader product pipeline. Board seats were granted to Kanishka Pothula from Nextech Invest and Brian Matesic from Norwest.
Company Information
Company
Matchpoint Therapeutics
Location
Watertown, Massachusetts, United States
About
Matchpoint Therapeutics is a biotechnology company based in Watertown, Massachusetts, pioneering the discovery of precision covalent medicines for autoimmune and inflammatory diseases. The company specializes in rationally designed covalent small molecules targeting historically hard-to-drug biovalidated targets. Its discovery platform integrates expertise in chemical biology, covalent chemistry, structure-based drug design, and computational sciences. The company has a focused pipeline of first-in-class programs and a discovery collaboration with Novartis.
Fundz sees it the moment Matchpoint Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
WatertownBiotechnologyTherapeutics